Review

Influence of Hyperhomocysteinemia on the Cellular Redox State – Impact on Homocysteine-Induced Endothelial Dysfunction

Norbert Weiss1*, Stanley J. Heydrick2, Otilia Postea1, Christiane Keller1, John F. Keaney Jr.2 and Joseph Locatello2

1 Medizinische Poliklinik – Innenstadt, Klinikum der Universität München, Munich, Germany
2 Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA

Hyperhomocysteinemia is an independent risk factor for the development of atherosclerosis. An increasing body of evidence has implicated oxidative stress as being contributory to homocysteine’s deleterious effects on the vasculature. Elevated levels of homocysteine may lead to increased generation of superoxide by a biochemical mechanism involving nitric oxide synthase, and, to a lesser extent, by an increase in the chemical oxidation of homocysteine and other aminothiols in the circulation. The resultant increase in superoxide levels is further amplified by homocysteine-dependent alterations in the function of cellular antioxidant enzymes such as cellular glutathione peroxidase or extracellular superoxide dismutase. One direct clinical consequence of elevated vascular superoxide levels is the inactivation of the vasorelaxant messenger nitric oxide, leading to endothelial dysfunction. Scavenging of superoxide anion by either superoxide dismutase or 4,5-dihydroxybenzene 1,3-disulfonate (Tiron) reverses endothelial dysfunction in hyperhomocysteinemic animal models and in isolated aortic rings incubated with homocysteine. Similarly, homocysteine-induced endothelial dysfunction is also reversed by increasing the concentration of the endogenous antioxidant glutathione or overexpressing cellular glutathione peroxidase in animal models of mild hyperhomocysteinemia. Taken together, these findings strongly suggest that the adverse vascular effects of homocysteine are at least partly mediated by oxidative inactivation of nitric oxide. Clin Chem Lab Med 2003; 41(11):1455–1461

Key words: Homocysteine; Oxidant stress; Nitric oxide; Endothelial dysfunction.

Abbreviations: CBSβ/–, heterozygous cystathionine β-synthase-deficient mice; DCF, 2',7'-dichlorofluoresceine; eNOS, endothelial nitric oxide synthase; GPx-1, cellular isofrom of glutathione peroxidase; L-NAME, L-nitroarginine methyl ester; NO, nitric oxide; TBARs, thiobarbituric acid reactive substances.

Introduction

Elevated plasma levels of homocysteine (hyperhomocysteinemia) have been established as a risk factor for atherothrombotic vascular disease during the last two decades. The pathobiological mechanisms by which homocysteine promotes atherothrombosis are not completely understood as yet. One well-supported but not universally accepted hypothesis suggests that hyperhomocysteinemia leads to increased oxidant stress in the vasculature. This effect may be central to its promotion of vascular pathology, partly by decreasing the bioavailability of the endothelial antithromogenic signalling molecule nitric oxide. The resulting endothelial dysfunction is contributory to decreased vasodilator capacity, activation of circulating leukocytes and platelets, activation of prothrombotic and inhibition of fibrinolytic mechanisms, and stimulation of vascular smooth muscle cell proliferation. All these effects participate in the initiation and progression of atherosclerotic lesions and thrombus formation (1). The purpose of this article is to review recent advances in understanding the mechanisms by which elevated levels of homocysteine induce vascular oxidant stress, and the impact of such stress on endothelial function in the clinical setting.

Hyperhomocysteinemia Is Associated with Increased Superoxide Output

Experiments in hyperhomocysteinemic animals and incubation of cultured endothelial cells with homocysteine indicate that elevated levels of homocysteine lead to increased formation of reactive oxygen species. Aortic tissue from mildly hyperhomocysteinemic heterozygous cystathionine β-synthase-deficient (CBSβ/–) mice produces more superoxide anion compared to wild-type mice (2), as measured by the lucigenin chemiluminescence assay or the cytochrome c assay. The same effect could be demonstrated in cultured endothelial cells incubated with homocysteine (3). This enhanced superoxide formation seems to be a critical determinant of homocysteine-induced endothelial dysfunction as scavenging of superoxide anion by either superoxide dismutase or 4,5-dihydroxybenzene 1,3 disulfonate (Tiron) has been shown to reverse endothelial dysfunction in hyperhomocysteinemic animal models (2, 4) and in isolated aortic rings incubated with homocysteine (3).

Superoxide anion reacts with nitric oxide in a diffusion-limited reaction to form peroxynitrite (5), which does not induce vasorelaxation (6), and is itself highly
reactive. The potential physiological relevance of this reaction is demonstrated by immunohistochemical and immunoblot data showing an increase in protein tyrosine nitration, a marker of peroxynitrite-dependent protein oxidation, in vascular tissues from mildly hyperhomocysteinemic mice (2), and in lysates from aortic rings cultured in homocysteine-containing media (7).

The role of hydrogen peroxide, which is produced from superoxide via superoxide dismutase, in homocysteine-induced endothelial toxicity in vitro is somewhat more nebulous. Early studies demonstrated that catalase inhibits the homocysteine-induced lysis of endothelial cells in the presence of transition metals or ceruloplasmin (8, 9), but this lytic effect of homocysteine was only observed at concentrations far exceeding those observed in the most severe cases of hyperhomocysteinemia. More recently, we (Figure 1) and others (10–12) have observed a homocysteine dose-dependent increase in the fluorescence of an hydrogen peroxide-sensitive fluorescent probe, 2',7'-dichlorofluoresceine (DCF), in cultured endothelial cells, but the interpretation of these results is tempered by the observation that DCF also fluoresces when it reacts with peroxynitrite and reactive oxygen species other than hydrogen peroxide.

Mechanisms of Increased Vascular Oxidant Stress in Hyperhomocysteinemia

Elevation of the oxidation rate of homocysteine in hyperhomocysteinemia

Homocysteine is an intermediate in the methionine cycle, the function of which is to generate one-carbon methyl groups in the form of S-adenosylmethionine for transmethylation reactions (13). The essential amino acid methionine is the precursor of homocysteine. In mammals, homocysteine can be diverted from the methionine cycle into the transsulfuration pathway to generate the non-essential amino acid cysteine, or it can be remethylated to methionine. Chemically, methionine contains a sulfide sulfur (R-S-R'), whereas homocysteine and cysteine are sulfhydryl compounds (R-SH). Compounds containing a free sulfhydryl group are known as “thiols.” Other biologically relevant low-molecular-weight thiols are glutathione, coenzyme A, and dihydrolipoic acid. Under aerobic conditions (i.e., in the presence of molecular oxygen as an electron acceptor) and at physiological pH, thiols such as homocysteine, oxidize to form disulfides, according to the general reaction $2 \text{RSH} + \text{O}_2 \rightleftharpoons \text{RSSR} + \text{H}_2\text{O}_2$. In plasma, this reaction can be catalyzed by transition metals such as copper and cobalt (the former present in the circulation associated with albumin and ceruloplasmin, the latter with cobalamin). Homocysteine has classically been thought to autooxidize readily via this mechanism to form homocysteine, oxidize other thiols such as cysteine and glutathione to form mixed disulfides, or oxidize free cysteine residues on proteins and peptides to form mixed disulfides (Figure 2). This notion is supported by the observation that 1% or less of total homocysteine species consists of free homocysteine in the plasma of healthy humans under physiological conditions, whereas 5–15% consist of homocysteine, another 5–15% are mixed disulfides (cysteine-homocysteine or glutathione-homocysteine), and more than 70% are protein-bound (14). Moreover, a decreased ratio of reduced to total aminothiols in plasma has been demonstrated in experimental hyperhomocysteinemia after a methionine challenge (14–16) and in hyperhomocysteinemic patients (17–20). More recent evi-
Evidence, however, suggests that oxidized forms of homocysteine in plasma arise primarily via disulfide exchange, with only a small fraction resulting from direct homocysteine oxidation (21). Hence, the contribution of direct homocysteine oxidation to homocysteine-induced vascular oxidative stress may not be as important as enzymatic mechanisms.

**Involvement of nitric oxide synthase in the generation of reactive oxygen species**

Recent *in vitro* experiments (SH, NW, JL, JK, unpublished observations) suggest that homocysteine-induced oxidant stress is stereospecific for the naturally occurring L-isofoms, indicating a biochemical rather than chemical basis for the effect. In these experiments, increased lipid peroxidation was observed in endothelial cells incubated with L-homocysteine, but not with D-homocysteine, as measured by total isoprostane F<sub>2α</sub>-III and thiobarbituric acid reactive substances (TBARS) levels in the supernatant of endothelial cell cultures. Stereospecificity was also observed for DCF fluorescence *in situ*, indicating a parallel effect on overall reactive oxygen species content. Enhanced lipid peroxidation and DCF-fluorescence was not observed with either cysteine or glutathione, and was not due to extracellular thiol oxidation, as it could be fully replicated with the oxidized disulfide form of homocysteine, L-homocystine.

Mechanistically, this pro-oxidant effect seems to be dependent upon both endothelial nitric oxide synthase and superoxide anion. Pharmacological inhibition of endothelial nitric oxide synthase with L-nitroarginine methyl ester (L-NAME) completely blocked the homocysteine-dependent stimulation of reactive oxygen species formation as measured by DCF-fluorescence. Furthermore, L-NAME completely abrogated both the homocysteine-dependent increases in isoprostane F<sub>2α</sub>-III formation and DCF fluorescence. Similarly, transfection of endothelial cells with superoxide dismutase cDNA blocked the effect of homocysteine on endothelial cell lipid peroxidation, whereas addition of extracellular superoxide dismutase had no effect. Importantly, neither the addition of extracellular catalase nor loading cells with catalase had any effect on lipid peroxidation, indicating that hydrogen peroxide is not involved in this process.

The most straightforward explanation for these results would be that homocysteine induces increased...
formation of peroxynitrite. Unlike superoxide, peroxynitrite is both able to initiate lipid peroxidation (22) and to react with DCF (23). Peroxynitrite has a short half-life, which makes its detection difficult in biological systems (24), but may react with cellular tyrosine residues to form nitrosated endproducts. As mentioned earlier, immunostaining for one such endproduct, 3-nitrotyrosine, was positive in aortic tissue from mildly hyperhomocysteinemic CBS(+/−) mice compared with wild-type mice (2), as was an immunoblot analysis for 3-nitrotyrosine of protein lysates from aortic rings cultured in homocysteine-containing media (7).

Although the precise mechanism by which homocysteine may induce increased peroxynitrite formation remains to be elucidated, two potential mechanisms include endothelial nitric oxide synthase “uncoupling” (5, 25), in which endothelial nitric oxide synthase is the source of superoxide (and peroxynitrite); and increased superoxide production from other enzymatic sources, in which some of the excess superoxide reacts with nitric oxide to form peroxynitrite (Figure 3).

Inhibition of cellular antioxidant enzymes by homocysteine

The cellular defense system against reactive oxygen species includes several antioxidant enzymes (Figure 4) and non-enzymatic antioxidants, such as α-tocopherol, ascorbic acid, β-carotene, and glutathione. Homocysteine has been shown in particular to disrupt the normal function of two important cellular antioxidant enzymes, the cellular isoform of glutathione peroxidase (GPx-1) and superoxide dismutase.

Homocysteine, but not other low-molecular-weight thiols, decreases both the expression and specific activity of GPx-1 as shown in vitro and in vivo (26–31). This key enzyme for the cellular defense against oxidant stress uses glutathione to reduce hydrogen peroxide and lipid peroxides to their respective alcohols (32), and may also act as a peroxynitrite reductase (33). Transition metal ions such as iron and copper catalyze the breakdown of hydrogen peroxide to form hydroxyl radical (·OH), which is highly reactive and causes lipid peroxidation, among its numerous effects; and hydroxide anion (OH−), which promotes alkaline tissue damage. This process is offset in part by catalase and GPx-1-dependent reduction of H2O2 to H2O. Elevated levels of lipid peroxides are accompanied by an increase in peroxyl radicals, which can inactivate nitric oxide through the formation of lipid peroxynitrites (34, 35). Thus a deficiency of GPx-1 may lead to a decrease in bioavailable nitric oxide via at least two mechanisms, an increase in reactive oxygen species and an increase in lipid hydroperoxides. In support of this hypothesis we have shown previously that mice deficient in GPx-1 have endothelial dysfunction owing to decreased bioavailable endothelium-derived nitric oxide; increased oxidative stress and increased lipid hydroperoxide generation as measured by increased tissue isoprostane F2α-Ili and hepatic phospholipid hydroperoxide levels; and increased nitrosative stress, as indicated by increased immunostaining for 3-nitrotyrosine in aortic tissue of GPx-1 knockout mice compared to wild-type mice (36).

Extracellular superoxide dismutase is a secreted glycoprotein with an affinity for heparin-like glycosaminoglycans. It is present in the circulation in equilibrium between the glycosaminoglycans on the endothelial surface and the plasma phase, and acts as the principal enzymatic scavenger of superoxide in the extracellular space (37, 38). The plasma levels of extracellular superoxide dismutase correlate positively with plasma homocysteine levels in homocystinuric patients (39) and in patients with mild hyperhomocysteinemia (40). This effect is caused by decreased binding of extracellular superoxide dismutase to endothelial cell surfaces by alterations in the endothelial heparan sulfate proteoglycan by homocysteine (41). This effect may result in a loss of the ability to protect the endothelial surface from oxidative stress, although this hypothesis has not yet been definitively proven.

In summary, experimental data suggest that elevated levels of homocysteine lead to increased vascular generation of reactive oxygen species, primarily by a mechanism involving nitric oxide synthase, and secondarily due to increased homocysteine oxidation. These effects are further amplified by alterations in the function of important cellular antioxidant enzymes. The resultant vascular oxidant stress may lead to vascular dysfunction.

Impact of Increased Vascular Oxidant Stress on Homocysteine-Induced Endothelial Dysfunction

Endothelial dysfunction, which can be defined in part as an impairment of endothelium-dependent vasoreactivity and regulation of blood flow in the presence of normal endothelium-independent vasodilation, appears to be a key event in homocysteine-induced vascular pathobiology (1). Endothelial dysfunction has been demonstrated in several different animal models of mild hyperhomocysteinemia, including hyperhomocysteinemia induced by vitamin-deficient and methionine-enriched diets in cynomolgus monkeys (42) or rats (43, 44), by heterozygous disruption of the cystathionine β-synthase gene in mice (CBS(+/−) mice) (2, 30, 31), or by the combination of genetic and dietary manipulation (45). Endothelial dysfunction has also been demonstrated in healthy humans with either acutely elevated plasma homocysteine levels following an oral methionine challenge (46–56) or with chronic, mild hyperhomocysteinemia (57–59).

In these studies, homocysteine impaired endothel-
Plasma homocysteine levels cannot, however, be normalized by vitamin supplementation in all cases. For example, hyperhomocysteinemia persists even with folic acid treatment (1–5 mg/day) in many patients with chronic renal failure (66). Alternative therapeutic options directed at reducing the cardiovascular risk associated with hyperhomocysteinemia are warranted in these subgroups of patients. Antioxidant therapy seems to be one such strategy. In this context it is worth mentioning that, although the results of trials of antioxidants for reducing cardiovascular morbidity and mortality in the general population were disappointing and did not show a benefit (67), there are two clinical trials in patients with chronic renal failure that showed a significant benefit of α-tocopherol or the thiol antioxidant N-acetylcysteine on cardiovascular morbidity and mortality (68, 69). Whether or not this relates to an effect of antioxidants on improving homocysteine-induced endothelial dysfunction in patients with chronic renal failure remains to be determined. Nevertheless the experimental data reviewed here and the results of these two clinical trials encourage further evaluation of the effect of antioxidant strategies in selected groups of patients at risk of cardiovascular disease, as in patients with hyperhomocysteinemia who do not respond to folic acid supplementation.

**Acknowledgements**

Supported by grants from the Deutsche Forschungsgemeinschaft (WE 1984/2-1) to N.W. and from the National Institutes of Health (HL55993, HL58976, HL61828, and HV28178) to J.L.

**References**


24. Rubbo H, Freeman BA. Nitric oxide regulation of lipid oxidation reactions: formation and analysis of nitrogen-con-


Received 13 May 2003, revised 21 July 2003, accepted 26 July 2003

Corresponding author: Priv.-Doz. Dr. med. Norbert Weiss, Medizinische Poliklinik – Innenaerztliche Klinik der Universität München, Pettenkoferstraße 8a, 80336 Munich, Germany Phone: +49-89-5160-3511, Fax: +49-89-5160-3559, E-mail: Norbert.Weiss@med.uni-muenchen.de